CERo Therapeutics Holdings Beheer

Beheer criteriumcontroles 0/4

De CEO CERo Therapeutics Holdings is Chris Ehrlich, benoemd in Sep2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 3.86% van de aandelen van het bedrijf, ter waarde $ 851.92K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.1 jaar en 0.8 jaar.

Belangrijke informatie

Chris Ehrlich

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	3.9%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

CEO

Chris Ehrlich (54 yo)

less than a year

Tenure

Mr. Christopher B. Ehrlich, M.B.A. also known as Chris, serves as Chief Executive Officer & Chair of CERo Therapeutics, Inc. Mr. Ehrlich was Director at ProLynx Inc since September 2022 until 2023. He serv...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Ehrlich	CEO & Chair	less than a year	geen gegevens	3.86% $ 851.9k
Brian Atwood	President & Director	no data	geen gegevens	13.13% $ 2.9m
Lawrence Corey	Co-founder & Head of Scientific Advisory Board	no data	geen gegevens	5.62% $ 1.2m
Andrew Kucharchuk	CFO & Director	less than a year	geen gegevens	0% $ 0
Kristen Pierce	Chief Development Officer & Director	less than a year	geen gegevens	0% $ 0

0.08yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CERO wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.1 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Ehrlich	CEO & Chair	less than a year	geen gegevens	3.86% $ 851.9k
Brian Atwood	President & Director	less than a year	geen gegevens	13.13% $ 2.9m
Lawrence Corey	Co-founder & Head of Scientific Advisory Board	no data	geen gegevens	5.62% $ 1.2m
Andrew Kucharchuk	CFO & Director	less than a year	geen gegevens	0% $ 0
Kristen Pierce	Chief Development Officer & Director	less than a year	geen gegevens	0% $ 0
Kathleen LaPorte	Independent Director	less than a year	geen gegevens	0.65% $ 142.9k
Shami Patel	Independent Director	less than a year	geen gegevens	geen gegevens
Adrian Bot	Scientific Advisor	no data	geen gegevens	geen gegevens
Antonio Lanzavecchia	Scientific Advisor	no data	geen gegevens	geen gegevens
Rafi Ahmed	Scientific Advisor	no data	geen gegevens	geen gegevens
Michael Byrnes	Independent Director	less than a year	geen gegevens	0% $ 0
Lindsey Rolfe	Independent Director	less than a year	geen gegevens	0% $ 0

0.8yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CERO wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw bestuur.

CERo Therapeutics Holdings Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

CERo Therapeutics Holdings, Inc. Appoints Shami Patel to the Board as Class III Director

CERo Therapeutics Holdings, Inc. Appoints Andrew Albert Kucharchuk as Chief Financial Officer

High number of new and inexperienced directors

Recent updates

CERo Announces Reverse Stock Split to Regain Compliance with the Bid Price Requirement

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics Holdings, Inc. announced delayed 10-Q filing

Nasdaq Determines to Delist CERo Therapeutics Holdings' Securities from The Nasdaq Global Market on November 8, 2024 Due to Failure to Regain Compliance with the MVLS Requirement within the Cure Period

CERo Therapeutics Holdings Receives Low Price Deficiency Letter from Nasdaq and Nasdaq Determines to Delist its Securities from The Nasdaq Global Market

CERo Therapeutics Holdings, Inc. Announces Submission of IND Clinical Hold Complete Response Letter

CERo Therapeutics Holdings, Inc. Appoints Shami Patel to the Board as Class III Director

CERo Therapeutics Holdings, Inc. Appoints Andrew Albert Kucharchuk as Chief Financial Officer

CERo Therapeutics Holdings, Inc. announced that it expects to receive $1.2 million in funding

CERo Therapeutics Holdings, Inc. announced that it expects to receive $1.25 million in funding

CERo Therapeutics Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement and MVPHS Requirement

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. announced delayed 10-Q filing

CERo Therapeutics Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum $50 Million Market Value of Listed Securities Requirement Set Forth in Nasdaq Listing Rule 5450(b)(2)(A)

CERo Therapeutics Holdings, Inc. announced delayed annual 10-K filing

CERo Therapeutics Holdings, Inc. announced delayed annual 10-K filing

New major risk - Shareholder dilution

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients

Phoenix Biotech Acquisition Corp.(NasdaqGM:CERO) dropped from NASDAQ Composite Index

CERo Therapeutics Holdings, Inc. announced that it has received $9.4 million in funding

New minor risk - Share price stability

Phoenix Biotech Acquisition Corp. announced that it expects to receive $2 million in funding from Keystone Capital Partners LLC

High number of new and inexperienced directors

Phoenix Biotech Acquisition Corp. Receives Non-Compliance Letter from Nasdaq related to Listing Rule 5450(a)(2

Phoenix Biotech Acquisition Corp. Receives Non-Compliance Letter from Nasdaq related to Listing Rule 5450(a)(2

CERo Therapeutics, Inc. entered into a definitive business combination agreement to acquire Phoenix Biotech Acquisition Corp. (NasdaqGM : PBAX) in a reverse merger transaction for an implied enterprise value of approximately $110 million.

Phoenix Biotech Acquisition Corp. (NasdaqGM:PBAX) entered into a business combination agreement to acquire Intrinsic Medicine, Inc. for approximately $140 million.

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd